Browsing Tag
clinical trials
134 posts
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.
Biofrontera reaches key clinical milestone with database locks across two ongoing studies
Find out why Biofrontera Inc.’s database locks for two clinical studies strengthen regulatory readiness and advance key data milestones.
FDA green light fast-tracks Diamyd Medical’s type 1 diabetes verdict by nine months
Diamyd Medical accelerates its Phase 3 type 1 diabetes trial after FDA alignment. Find out what the earlier data readout means for approval prospects.
Can OrsoBio’s TLC-6740 combination data reopen the race for post-GLP obesity differentiation?
OrsoBio’s TLC-6740 combo data hints at a new way to extend GLP-1 weight loss without higher doses. Read what this means for obesity drug development.
Anixa Biosciences (NASDAQ: ANIX) moves forward as Phase 1 breast cancer vaccine data clear safety and immune hurdles
Anixa Biosciences’ breast cancer vaccine met Phase 1 safety and immune response targets. Find out how Keytruda combinations could transform care.
Innovent Biologics launches clinical trial for IBI3011 to target gout and inflammatory diseases in China
Find out how Innovent Biologics is targeting unmet needs in gout with IBI3011, a first-in-class anti-IL-1RAP antibody now in clinical trials. Read more.
Briquilimab shows promising asthma signal in ETESIAN study as Jasper Therapeutics resolves BEACON probe
Discover how Jasper Therapeutics reignited confidence in briquilimab with new asthma data and a clarified BEACON investigation.
Next-gen RNA therapy SIL204 passes key safety milestone as Silexion Therapeutics prepares Phase 2/3 pancreatic cancer study
Find out how Silexion Therapeutics is advancing SIL204 after a key safety milestone in pancreatic cancer research.
Can C4 Therapeutics (CCCC) balance dilution and growth with its $400m shelf plan?
C4 Therapeutics files $400M shelf to support oncology trials. Find out what this means for investors and the company’s future strategy.
Biotech breakthrough in PTSD? Silo Pharma and Allucent move toward FDA IND filing for SPC-15 therapy
Silo Pharma partners with Allucent to advance its planned FDA IND for intranasal PTSD therapeutic SPC-15. Find out how this collaboration could shape future mental health treatment.